Covid-19 Research

Clinical Trials

Reviewing Clinical Trials and Meta-Analyses to Assess the Efficacy and Safety of Huachansu in Cancer Treatment

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Clinical Trials
Subject Medicine Group
OCLC JBRES Record
Aline Genbauffe, Laura Soumoy, Florence Lefranc and Fabrice Journe*
Issue: Volume5-Issue9
Pages: 1132-1139
Received: 2024-08-30
Accepted: 2024-09-20
Published: 2024-09-20

Abstract

Traditional Chinese Medicine (TCM), including herbal remedies and animal secretions like HuaChansu, also called Cinobufacini, has gained attention for its therapeutic efficacy in cancer treatment. HuaChansu, extracted from the skin of toads from the genus Bufo, has been used traditionally for various diseases and recently explored for its anti-cancer properties attributed to bufadienolides like bufalin, resibufogenin, and cinobufagin. Clinical studies and meta-analyses have evaluated its efficacy and safety across various cancers. For hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer, pilot studies and clinical trials showed HuaChansu's potential for disease stabilization with minimal toxicity. In breast cancer, a meta-analysis suggested that HuaChansu combined with chemotherapy improves response rates and quality of life. Studies on gallbladder and gastric cancers indicated similar benefits, enhancing therapeutic effects and reducing side effects. In lung cancer, HuaChansu improved survival rates and quality of life when combined with chemotherapy, though placebo-controlled trials are needed. For liver cancer, meta-analyses and randomized controlled trials demonstrated improved survival rates and reduced recurrence when HuaChansu was used with transarterial chemoembolization. These findings underscore HuaChansu potential as a complementary cancer treatment, warranting further research to optimize its dosage and administration for enhanced efficacy.

FullText HTML FullText PDF DOI: 10.37871/jbres2001 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Genbauffe A, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Genbauffe A, Soumoy L, Lefranc F, Journe F. Reviewing Clinical Trials and Meta-Analyses to Assess the Effi cacy and Safety of Huachansu in Cancer Treatment. J Biomed Res Environ Sci. 2024 Sept 20; 5(9): 1132-1139. doi: 10.37871/jbres2001, Article ID: JBRES2001, Available at: https://www.jelsciences.com/articles/jbres2001.pdf

Subject area(s)

Clinical Trials

References

  1. Wang CY, Bai XY, Wang CH. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med. 2014;42(3):543-59. doi: 10.1142/S0192415X14500359. PMID: 24871650.
  2. Zuo Q, Xu DQ, Yue SJ, Fu RJ, Tang YP. Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini. Chin J Integr Med. 2024 Apr;30(4):366-378. doi: 10.1007/s11655-024-3708-6. Epub 2024 Jan 12. PMID: 38212503.
  3. Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, Han J. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015 Feb;9(1):16-34. doi: 10.5582/bst.2015.01019. PMID: 25787906.
  4. Zhan X, Wu H, Wu H, Wang R, Luo C, Gao B, Chen Z, Li Q. Metabolites from Bufo gargarizans (Cantor, 1842): A review of traditional uses, pharmacological activity, toxicity and quality control. J Ethnopharmacol. 2020 Jan 10;246:112178. doi: 10.1016/j.jep.2019.112178. Epub 2019 Aug 21. PMID: 31445132.
  5. Soumoy L, Ghanem GE, Saussez S, Journe F. Bufalin for an innovative therapeutic approach against cancer. Pharmacol Res. 2022 Oct;184:106442. doi: 10.1016/j.phrs.2022.106442. Epub 2022 Sep 9. PMID: 36096424.
  6. Nik Nabil WN, Dai R, Liu M, Xi Z, Xu H. Repurposing cardiac glycosides for anticancer treatment: a review of clinical studies. Drug Discov Today. 2024 Aug 3;29(10):104129. doi: 10.1016/j.drudis.2024.104129. Epub ahead of print. PMID: 39098384.
  7. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009 Nov 15;115(22):5309-18. doi: 10.1002/cncr.24602. PMID: 19701908; PMCID: PMC2856335.
  8. Soumoy L, Genbauffe A, Mouchart L, Sperone A, Trelcat A, Mukeba-Harchies L, Wells M, Blankert B, Najem A, Ghanem G, Saussez S, Journe F. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell Int. 2024 Jan 4;24(1):8. doi: 10.1186/s12935-023-03196-y. PMID: 38178183; PMCID: PMC10765859.
  9. Soumoy L, Wells M, Najem A, Krayem M, Ghanem G, Hambye S, Saussez S, Blankert B, Journe F. Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms. Biology (Basel). 2020 Aug 10;9(8):218. doi: 10.3390/biology9080218. PMID: 32785105; PMCID: PMC7464305.
  10. Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, Cohen L. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer. 2012 Jul 24;107(3):411-6. doi: 10.1038/bjc.2012.283. Epub 2012 Jul 10. PMID: 22782343; PMCID: PMC3405220.
  11. Xu J, Li D, Du K, Wang J. Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2020 Sep 19;2020:4953539. doi: 10.1155/2020/4953539. PMID: 33014106; PMCID: PMC7520696.
  12. Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol. 2008 Sep 7;14(33):5210-6. doi: 10.3748/wjg.14.5210. PMID: 18777599; PMCID: PMC2744012.
  13. Halaseh SA, Halaseh S, Shakman R. A Review of the Etiology and Epidemiology of Gallbladder Cancer: What You Need to Know. Cureus. 2022 Aug 22;14(8):e28260. doi: 10.7759/cureus.28260. PMID: 36158346; PMCID: PMC9491243.
  14. Yan X, Lei L, Li H, Cao M, Yang F, He S, Zhang S, Teng Y, Li Q, Xia C, Chen W. Stomach cancer burden in China: Epidemiology and prevention. Chin J Cancer Res. 2023 Apr 30;35(2):81-91. doi: 10.21147/j.issn.1000-9604.2023.02.01. PMID: 37180831; PMCID: PMC10167608.
  15. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PMID: 38572751.
  16. Zhang X, Yuan Y, Xi Y, Xu X, Guo Q, Zheng H, Hua B. Cinobufacini Injection Improves the Efficacy of Chemotherapy on Advanced Stage Gastric Cancer: A Systemic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2018 Sep 4;2018:7362340. doi: 10.1155/2018/7362340. PMID: 30254688; PMCID: PMC6142757.
  17. Wu J, Zhang D, Ni M, Xue J, Wang K, Duan X, Liu S. Effectiveness of Huachansu injection combined with chemotherapy for treatment of gastric cancer in China: a systematic review and Meta-analysis. J Tradit Chin Med. 2020 Oct;40(5):749-757. doi: 10.19852/j.cnki.jtcm.2020.05.004. PMID: 33000575.
  18. Sun H, Wang W, Bai M, Liu D. Cinobufotalin as an effective adjuvant therapy for advanced gastric cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther. 2019 Apr 26;12:3139-3160. doi: 10.2147/OTT.S196684. PMID: 31118669; PMCID: PMC6507077.
  19. Bu ZJ, Wan SR, Steinmann P, Yin ZT, Tan JP, Li WX, Tang ZY, Jiang S, Ye MM, Xu JY, Zheng YY, Wang XH, Liu JP, Liu ZL. Effectiveness and Safety of Chinese Herbal Injections Combined with SOX Chemotherapy Regimens for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis. J Cancer. 2024 Jan 1;15(4):889-907. doi: 10.7150/jca.91301. PMID: 38230219; PMCID: PMC10788720.
  20. Xu ZY, Jin CJ, Zhou CC, Wang ZQ, Zhou WD, Deng HB, Zhang M, Su W, Cai XY. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol. 2011 Jul;137(7):1117-22. doi: 10.1007/s00432-011-0975-3. Epub 2011 Feb 5. PMID: 21298288.
  21. Jie C, Jian Z, Di Y, Jin C. Clinical curative effect on non-small cell lung cancer patients by cinobufacini injection combined first line chemotherapy. Journal of International Oncology. 2016;43(10):741.
  22. Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial. Complement Ther Med. 2016 Feb;24:55-62. doi: 10.1016/j.ctim.2015.12.006. Epub 2015 Dec 17. PMID: 26860802.
  23. Jiang Y, Wu LB, Shen LP, Zhang P, Jiang WJ, Tian JH, Liu LS. [Effect of traditional Chinese medicine treatment as maintenance therapy on regulating the serum concentration of sCTLA-4 in patients with advanced non-small-cell lung cancer and its relationship with prognosis]. Zhonghua Zhong Liu Za Zhi. 2016 Oct 23;38(10):757-762. Chinese. doi: 10.3760/cma.j.issn.0253-3766.2016.10.009. PMID: 27784460.
  24. Xu Y, Han D, Feng FC, Wang ZC, Gu C, Peng WP, He HL, Zhou XM. [Meta-analysis of Cinobufacini Injection combined with platinum-contained first-line chemotherapy in treatment of non-small cell lung cancer]. Zhongguo Zhong Yao Za Zhi. 2019 Nov;44(21):4728-4737. Chinese. doi: 10.19540/j.cnki.cjcmm.20190505.501. PMID: 31872671.
  25. Peng W, Xu Y, Feng F, Gu C, Wang Z, Han D, Zhou X, He H. Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC. Evid Based Complement Alternat Med. 2021 Aug 21;2021:5596415. doi: 10.1155/2021/5596415. PMID: 34471417; PMCID: PMC8405304.
  26. Tan X, Liang X, Xi J, Guo S, Meng M, Chen X, Li Y. Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021 Sep 10;100(36):e27161. doi: 10.1097/MD.0000000000027161. PMID: 34516509; PMCID: PMC8428704.
  27. Zhang F, Yin Y, Xu T. Cinobufotalin injection combined with chemotherapy for the treatment of advanced NSCLC in China: A PRISMA-compliant meta-analysis of 29 randomized controlled trials. Medicine (Baltimore). 2019 Aug;98(35):e16969. doi: 10.1097/MD.0000000000016969. PMID: 31464940; PMCID: PMC6736171.
  28. Li LL, Su YX, Mao Y, Jiang PY, Chu XL, Xue P, Jia BH, Zhu SJ. The Effectiveness and Safety of Cinobufotalin Injection as an Adjunctive Treatment for Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2021 Feb 5;2021:8852261. doi: 10.1155/2021/8852261. PMID: 33628320; PMCID: PMC7881937.
  29. Yang T, Wu C, Li P, Zhong Y, Wu W, Wang S, Yang X. Efficacy and Safety of Huachansu as an Adjuvant Therapy for Non-Small Cell Lung Cancer: An Overview of Systematic Reviews and Meta-Analyses. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241237234. doi: 10.1177/15347354241237234. PMID: 38469799; PMCID: PMC10935755.
  30. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019 Jan;72:28-36. doi: 10.1016/j.ctrv.2018.11.002. Epub 2018 Nov 12. PMID: 30447470.
  31. Ling CQ, Fan J, Lin HS, Shen F, Xu ZY, Lin LZ, Qin SK, Zhou WP, Zhai XF, Li B, Zhou QH; Chinese Integrative Therapy of Primary Liver Cancer Working Group. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. J Integr Med. 2018 Jul;16(4):236-248. doi: 10.1016/j.joim.2018.05.002. Epub 2018 May 17. PMID: 29891180.
  32. Wu T, Sun R, Wang Z, Yang W, Shen S, Zhao Z. A meta-analysis of Cinobufacini combined with transcatheterarterial chemoembolization in the treatment of advanced hepatocellular carcinoma. J Cancer Res Ther. 2014 Aug;10 Suppl 1:60-4. doi: 10.4103/0973-1482.139763. PMID: 25207894.
  33. Gao H, He J, Cheng CS, Zhuang L, Chen H, Meng Z. Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu - a single-center randomised controlled trial. BMJ Support Palliat Care. 2023 Jul 3:spcare-2022-003870. doi: 10.1136/spcare-2022-003870. Epub ahead of print. PMID: 37400162.
  34. Dong J, Zhai X, Chen Z, Liu Q, Ye H, Chen W, Ling C. Treatment of Huge Hepatocellular Carcinoma Using Cinobufacini Injection in Transarterial Chemoembolization: A Retrospective Study. Evid Based Complement Alternat Med. 2016;2016:2754542. doi: 10.1155/2016/2754542. Epub 2016 May 17. PMID: 27293455; PMCID: PMC4886065.
  35. Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou WP, Yang YK, Xu J, Qin X, Li LQ, Ling CQ. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med. 2013 Mar;11(2):90-100. doi: 10.3736/jintegrmed2013021. PMID: 23506690.
  36. Chen Z, Chen HY, Lang QB, Li B, Zhai XF, Guo YY, Yue XQ, Ling CQ. Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: a case-control trial. Chin J Integr Med. 2012 May;18(5):339-44. doi: 10.1007/s11655-012-1083-1. Epub 2012 May 2. PMID: 22549390.
  37. Xue T, Yu H, Feng W, Wang Y, Wu S, Wang L, Zhu P, Guan J, Sun Q. Efficacy and Safety of Hepatic Arterial Infusion Therapy with Cinobufacini in Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Retrospective Cohort Study. Cancer Manag Res. 2024 Mar 14;16:163-175. doi: 10.2147/CMAR.S440017. PMID: 38505102; PMCID: PMC10948332.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership